1. Home
  2. GLPG vs HURN Comparison

GLPG vs HURN Comparison

Compare GLPG & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLPG
  • HURN
  • Stock Information
  • Founded
  • GLPG 1999
  • HURN 2002
  • Country
  • GLPG Belgium
  • HURN United States
  • Employees
  • GLPG N/A
  • HURN N/A
  • Industry
  • GLPG Biotechnology: Pharmaceutical Preparations
  • HURN Professional Services
  • Sector
  • GLPG Health Care
  • HURN Consumer Discretionary
  • Exchange
  • GLPG Nasdaq
  • HURN Nasdaq
  • Market Cap
  • GLPG 2.1B
  • HURN 2.3B
  • IPO Year
  • GLPG 2005
  • HURN 2004
  • Fundamental
  • Price
  • GLPG $31.44
  • HURN $136.19
  • Analyst Decision
  • GLPG Sell
  • HURN Strong Buy
  • Analyst Count
  • GLPG 4
  • HURN 4
  • Target Price
  • GLPG $25.33
  • HURN $171.50
  • AVG Volume (30 Days)
  • GLPG 345.0K
  • HURN 220.6K
  • Earning Date
  • GLPG 07-23-2025
  • HURN 07-31-2025
  • Dividend Yield
  • GLPG N/A
  • HURN N/A
  • EPS Growth
  • GLPG N/A
  • HURN 37.96
  • EPS
  • GLPG N/A
  • HURN 5.74
  • Revenue
  • GLPG $323,674,692.00
  • HURN $1,556,665,000.00
  • Revenue This Year
  • GLPG N/A
  • HURN $11.50
  • Revenue Next Year
  • GLPG N/A
  • HURN $7.48
  • P/E Ratio
  • GLPG N/A
  • HURN $23.71
  • Revenue Growth
  • GLPG 5.43
  • HURN 9.24
  • 52 Week Low
  • GLPG $22.36
  • HURN $102.58
  • 52 Week High
  • GLPG $33.86
  • HURN $155.00
  • Technical
  • Relative Strength Index (RSI)
  • GLPG 47.00
  • HURN 54.68
  • Support Level
  • GLPG $31.39
  • HURN $134.94
  • Resistance Level
  • GLPG $32.43
  • HURN $136.99
  • Average True Range (ATR)
  • GLPG 0.77
  • HURN 3.43
  • MACD
  • GLPG -0.22
  • HURN 0.77
  • Stochastic Oscillator
  • GLPG 7.22
  • HURN 77.25

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

Share on Social Networks: